Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,786 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Platinol Clear all

Conditions: Mesothelioma
Interventions: Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 14
States / cities: San Francisco, California • New Haven, Connecticut • Tampa, Florida + 11 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol, Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: GU Research Network, LLC; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Multiple Myeloma
Interventions: myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D; Device · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Urothelial Cancer, Bladder Cancer
Interventions: Dato-DXd, Carboplatin, Cisplatin, Gemcitabine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 38
States / cities: Fullerton, California • Glendale, California • La Jolla, California + 34 more

Conditions: Urothelial Carcinoma Bladder, Androgen Receptor Positive
Interventions: Degarelix, Gemcitabine/Cisplatin; Drug · Combination Product
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Gemcitabine, LY293111, cisplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 6
States / cities: Birmingham, Alabama • Boston, Massachusetts • Manhasset, New York + 3 more

Conditions: Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Adrenocortical Carcinoma, Wilms Tumor, Rhabdomyosarcoma, Desmoplastic Small Round Cell Tumor
Interventions: CHPP of Cisplatin, Abdominal Surgery; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 3 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mesothelioma
Interventions: VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Head and Neck Cancer
Interventions: Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 14
States / cities: Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
Interventions: Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Quality-of-Life Assessment, Topotecan Hydrochloride, Vinorelbine Tartrate; Drug · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Cancer
Interventions: cisplatin, gemcitabine hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Gastric, or Gastroesophageal Junction Adenocarcinoma
Interventions: Tislelizumab, Placebo, Cisplatin, Oxaliplatin, Capecitabine, 5-Fluorouracil; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Sacramento, California • Newnan, Georgia • Columbus, Ohio + 3 more

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions: Durvalumab, Cisplatin, Carboplatin, Etoposide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Houston, Texas • Fairfax, Virginia

Conditions: Non Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Kentucky, Kentucky • Maryland City, Maryland • Langhorne, Pennsylvania

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Cetuximab, Cisplatin, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Biological · Drug · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Locally Advanced and Metastatic Solid Tumors
Interventions: Ociperlimab, Tislelizumab, Pemetrexed, Paclitaxel, Nab paclitaxel, Carboplatin, Cisplatin, Etoposide, 5fluorouracil, Oxaliplatin, Capecitabine; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 11
States / cities: Phoenix, Arizona • Fort Myers, Florida • Jacksonville, Florida + 8 more

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
Interventions: HIPEC, Carboplatin, Paclitaxel; Procedure · Drug
Lead sponsor: Andrea Jewell; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
Interventions: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics); Industry
Eligibility: 18 Years and older
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 12 more

Conditions: Advanced Solid Tumors
Interventions: M3814 100 mg, M3814 200 mg, M3814 300 mg, M3814 400 mg, M3814 50 mg, Fractionated RT, Cisplatin; Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 9
States / cities: Fresno, California • Fort Lauderdale, Florida • Miami, Florida + 6 more

Conditions: Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: R-(-)-gossypol acetic acid, cisplatin, etoposide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 4
States / cities: Sioux Falls, South Dakota • La Crosse, Wisconsin • Madison, Wisconsin

Conditions: Lung Cancer
Interventions: cisplatin, irinotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 8
States / cities: Millville, New Jersey • Mount Holly, New Jersey • Red Bank, New Jersey + 5 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 14
States / cities: Los Angeles, California • Jacksonville, Florida • Winter Haven, Florida + 11 more

Conditions: Stage II Lymphoepithelioma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: docetaxel, cisplatin, carboplatin, fluorouracil, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 18
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 12 more

Search by objective public record fields.

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

T790M Mutation Positive 2nd Line STandard of cAre Registry

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer

Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy